Aligos Therapeutics’ (ALGS) Buy Rating Reaffirmed at HC Wainwright

Aligos Therapeutics (NASDAQ:ALGS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $75.00 target price on the stock.

Aligos Therapeutics Stock Performance

Shares of NASDAQ:ALGS opened at $9.14 on Friday. The company has a market capitalization of $713.93 million, a PE ratio of -7.14 and a beta of 2.18. The company’s fifty day moving average is $13.19 and its 200-day moving average is $16.24. Aligos Therapeutics has a 52 week low of $8.70 and a 52 week high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The firm had revenue of $1.06 million for the quarter. During the same period in the prior year, the company posted ($10.75) earnings per share. On average, analysts forecast that Aligos Therapeutics will post -8.15 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALGS. Armistice Capital LLC acquired a new stake in Aligos Therapeutics in the 4th quarter valued at about $4,538,000. Opaleye Management Inc. bought a new stake in shares of Aligos Therapeutics during the fourth quarter valued at approximately $861,000. Acadian Asset Management LLC grew its stake in shares of Aligos Therapeutics by 17.6% during the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after purchasing an additional 98,628 shares during the last quarter. Finally, Altitude Crest Partners Inc. acquired a new stake in shares of Aligos Therapeutics in the fourth quarter valued at approximately $1,889,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).